« Previous
Next »
The American Journal of Medicine
Volume 121, Issue 1
, Pages
43-49
, January 2008
Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis
-
Effect of aspirin on (A) major cardiovascular events, (B) all-cause mortality, (C) MI, (D) stroke, and (E) major bleeding in patients with stable cardiovascular disease. Sizes of data markers are prop
Effect of aspirin on (A) major cardiovascular events, (B) all-cause mortality, (C) MI, (D) stroke, and (E) major bleeding in patients with stable cardiovascular disease. Sizes of data markers are proportional to the amount of data contributed by each trial. Test for heterogeneity for major cardiovascular events, P
=
.571; all-cause mortality, P
=
.557; MI, P
=
.650; stroke, P
=
.974; major bleeding, P
=
.581. CI
=
confidence interval; CV
=
cardiovascular; UK-TIA
=
United Kingdom Transient Ischemic Attack; SALT
=
Swedish Aspirin Low-Dose Trial; ESPS-2
=
European Stroke Prevention Study-2; SAPAT
=
Swedish Angina Pectoris Aspirin Trial. -
How does aspirin compare? Number needed to treat with aspirin, statins, and ACE inhibitor to prevent a death, major cardiovascular event, MI, or stroke. CV = cardiovascular; MI = myocardial infarctionHow does aspirin compare? Number needed to treat with aspirin, statins, and ACE inhibitor to prevent a death, major cardiovascular event, MI, or stroke. CV = cardiovascular; MI = myocardial infarction; ACE = angiotensin-converting enzyme.
PII: S0002-9343(07)00985-0
doi: 10.1016/j.amjmed.2007.10.002
© 2008 Elsevier Inc. All rights reserved.
« Previous
Next »
The American Journal of Medicine
Volume 121, Issue 1
, Pages
43-49
, January 2008

